文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性伴色素上皮脱离患者1年良好视力结局:影响治疗反应的因素

GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response.
PubMed 文献 · Retina · 2018-01-01

本回顾性连续病例系列纳入104眼(94例)未治疗的新生血管性年龄相关性黄斑变性伴色素上皮脱离(PED)>150 μm患者,接受阿柏西普(n=41)或雷珠单抗(n=63)治疗至少1年。1年时最佳矫正视力从基线20/63(60.8±15.9个ETDRS字母)提高至20/40(69.0±15.0个字母)(P=0.001),PED最大高度从370.8±205.6 μm降至238.8±178.5 μm(P=0.001)。视力改善与较低基线最佳矫正视力、中心凹下视网膜下液存在及女性性别相关;PED高度降低取决于较高基线PED高度和治疗药物,阿柏西普效果更强。

要点

  • 1年时最佳矫正视力从20/63提高至20/40(P=0.001),PED最大高度从370.8±205.6 μm降至238.8±178.5 μm(P=0.001)。
  • 视力改善与较低基线最佳矫正视力(P=0.001)、中心凹下视网膜下液存在(P=0.001)及女性性别(P=0.047)相关。
  • PED高度降低取决于较高基线PED高度(P=0.001)和治疗药物(P=0.008),阿柏西普效果更强。

核心结论

  • 雷珠单抗和阿柏西普在新生血管性年龄相关性黄斑变性伴PED患者中同等实现视力改善,主要受基线最佳矫正视力和中心凹下视网膜下液影响。
  • PED高度降低受基线高度和治疗药物影响,阿柏西普效果更强。
  • 该结果的临床意义需进一步研究。

研究设计与样本

  • 回顾性连续病例系列研究,纳入104眼(94例)未治疗的新生血管性年龄相关性黄斑变性伴PED>150 μm患者,接受阿柏西普(n=41)或雷珠单抗(n=63)治疗至少1年。
  • 采用逐步线性回归评估影响最佳矫正视力和PED反应的因素。

主要发现

  • 1年时最佳矫正视力从基线20/63(60.8±15.9个ETDRS字母)提高至20/40(69.0±15.0个字母)(P=0.001)。
  • PED最大高度从370.8±205.6 μm降至238.8±178.5 μm(P=0.001)。
  • 多变量分析显示视力改善与较低基线最佳矫正视力(P=0.001)、中心凹下视网膜下液存在(P=0.001)及女性性别(P=0.047)相关。
  • PED高度降低取决于较高基线PED高度(P=0.001)和治疗药物(P=0.008)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 该结果的临床意义需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate baseline and treatment factors influencing the response of pigment epithelial detachment (PED) in patients with treatment-naive neovascular age-related macular degeneration after 1 year of intravitreal anti-vascular endothelial growth factor treatment. METHODS: This retrospective consecutive case series study included 104 eyes (94 patients) with treatment-naive neovascular age-related macular degeneration and associated PED >150 μm treated with aflibercept (n = 41) or ranibizumab (n = 63) for at least 1 year. Stepwise linear regression was used to assess factors influencing best-corrected visual acuity and PED response. RESULTS: At 1 year, the best-corrected visual acuity improved from 20/63 (60.8 ± 15.9 Early Treatment of Diabetic Retinopathy Study letters) at baseline to 20/40 (69.0 ± 15.0 letters) (P = 0.001), and PED maximal height decreased from 370.8 ± 205.6 μm to 238.8 ± 178.5 μm (P = 0.001). Multivariate analysis revealed an association of the visual improvement with lower best-corrected visual acuity at baseline (P = 0.001), the presence of foveal subretinal fluid (P = 0.001), and female gender (P = 0.047). Pigment epithelial detachment height reduction was dependent on higher baseline PED height (P = 0.001) and treatment drug (P = 0.008). CONCLUSION: Visual improvement in neovascular age-related macular degeneration with PED was equally achieved with ranibizumab and aflibercept, influenced mainly by baseline best-corrected visual acuity and foveal subretinal fluid. Pigment epithelial detachment height reduction was influenced by baseline height and the treatment drug, favoring aflibercept for a stronger effect. The clinical significance of this result warrants further studies.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. de Massougnes S, Dirani A, Mantel I, et al. GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response. Retina. 2018. PMID: 28368974. doi:10.1097/IAE.0000000000001613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。